Christina Ruhlmann

Abstract submissions for #MASCC24 are now open! We encourage submissions from both new and experienced researchers. Submit your abstract by January 8 (or December 18 if you plan to apply for a Conference Scholarship). mascc.org/annualmeeting2… #SuppOnc @OncoAlert

We were excited to collaborate with @myESMO / EONS for two great joint sessions today at #ESMO24 and #EONS17!

Excellent presentation by Sofie Detlefsen of the results from the DANGER-emesis study demonstrating favourable safety profile during weekly administration of antiemetic prophylaxis with NEPA+dex during chemo-radiation for cervical cancer @CancerCareMASCC #MASCC24 #antiemetics

Our study groups are the core of MASCC. Thank you to each of our study group chairs and co-chairs for all of your hard work and leadership throughout the year! #MASCC24

#MASCC24 plenary session Christina Ruhlmann presents data on irAEs. Fascinating discussion of chronic irAEs that correlates well with our analysis by @SayaJacob3 @OncoAlert @UCSFCancer unclear impact on outcome and PROs. Multidisciplinary teams key.

Our Welcome Reception & Awards Ceremony is underway in the Exhibition Hall. Thanks to everyone for joining us and congratulations to each of this year’s award recipients! #MASCC24 #SuppOnc

Next up #MASCC24: @RuhlmannC discusses #immunotherapy toxicities and highlights the lack of guidance around metastatic #survivorship #survonc

@RuhlmannC reminds us of some 🦓 irAEs but they are l I’ll Elu to become more common as adjuvant treatment adopts moe immunotherapy #MASCC24

So happy to participate in #MASCC24 with my co-chair of the emerging agents toxicity working group @RuhlmannC. Come to Lille for this important and exciting meeting! @maryam_lustberg

Our first plenary session of #MASCC24 will focus on the management of emerging toxicities, chaired by Prof @alexchan928 and Dr Didier Mayeur. Speakers: Dr @hoperugo, Dr @RuhlmannC and Dr @ines_vazluis Register today! mascc.org/annualmeeting2… #supponc @OncoAlert

Recommendations for Global Curriculum in #MedicalOncology: result of great collaboration btw @myesmo & @ASCO and the full support of @JCOGO_ASCO & @ESMO_Open

@peterbachmd Great point! How do we get colleagues walking in that empty corridor? (was not that empty all the session 🙃)

Do we have the right priorities in oncology #ESMO2023 #ESMO23 - pictures taken a few minutes apart. Supportive care and Investigational therapy poster areas. Clinically these two are intertwined.

#ESMO23 💡is just around the corner! The #Supportive Care and #Palliative Care track delivers excellent content every day! See you in Madrid! @myESMO @ines_vazluis @bosnjaksupport @DrDavidHui @dorothy_keefe @AnneLetsch @ZimmTeamLab JWood GKreye JHerrstedt ASnegovoy TFusi MSaito

Proud to announce the set to ‘recruiting’ status of our RCT The iCaD Study, aiming to improve ICI induced colitis. Huge efforts, collaboration and funding made it possible for us to get so far - thanks to @Kjaer_Soeren @novonordiskfond @NEYEFonden @onko_ouh @OUHhospital #ICiTox

@hoperugo @CancerCareMASCC @UCSFCancer @OncoAlert Launch of the new @CancerCareMASCC Emerging Toxicities study group - looking forward to the great projects and collaborations with @hoperugo and great MASCC members

#MASCC23 Excited to help lead this new working group with the universal interest, enthusiasm and support of @CancerCareMASCC including cross disciplinary collaborations with #christinarhulmann. Many opportunities to improve #cancercare @UCSFCancer @OncoAlert

Fantastic presentations and well attended antiemetic poster session today at #MASCC23

Så er to super stærke ph.d.-studerende skudt i gang i ICiTox - Immunotoxicity Research Centre Region of Southern Denmark - @TenstadHelene og @Kjaer_Soeren #ICiTox @SUND_SDU @onko_ouh

@MIH06840674 @MSuppli @FYOncologist @DSth Enig @MIH06840674. Med denne vejledning kommer vi til at ændre praksis (DOAK til flere) og vi skal i den grad tænke os om ifht kontraindikationer. Algoritmen er ganske anvendelig og tager forbehold for det meste.

Behandlingsvejledning for VTE hos #kræftpatienter👇🏼

@MSuppli @MIH06840674 @FYOncologist @DSth Jeg vil anbefale Medicinrådets vejledning, da den er afgørende for hvilke præparater vi kommer til at anvende fremadrettet til flest patienter.

@MIH06840674 @RuhlmannC @FYOncologist @DSth Tak. Til at starte med handler det mest om hvilken vejledning man skal forholde sig til 🤷‍♂️

@FYOncologist @MSuppli @MIH06840674 CAT-rapporten og Medicinrådets nationale behandlingsvejledning for cancer associeret trombose er to selvstændige rapporter, der begge hviler på den forhåndenværende evidens på tilblivelsestidspunktet. Medicinrådets rapport afspejler den seneste evidens.

@MSuppli Ja, godt spørgsmål?? @MIH06840674 og @RuhlmannC hvad siger I?